TipRanks
Advertisement
Advertisement

FATE Stock Latest News

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
TipRanks NewswireFormer Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
14d ago
LLY
AMGN
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
PremiumClass Action
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
19d ago
FATE
Fate Therapeutics Secures CIRM Grant for FT819 Lupus Trial
PremiumCompany Announcements
Fate Therapeutics Secures CIRM Grant for FT819 Lupus Trial
23d ago
8K
FATE
Fate Therapeutics announces CIRM awarded it a $15M grant
PremiumThe Fly
Fate Therapeutics announces CIRM awarded it a $15M grant
26d ago
FATE
Fate Therapeutics announces clinical data from FT819 study
PremiumThe Fly
Fate Therapeutics announces clinical data from FT819 study
1M ago
FATE
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
PremiumCompany AnnouncementsFate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
2M ago
FATE
Fate Therapeutics Advances FT819 Cell Therapy Into Phase 2 Lupus Nephritis Trial
Premium
Company Announcements
Fate Therapeutics Advances FT819 Cell Therapy Into Phase 2 Lupus Nephritis Trial
2M ago
FATE
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
Premium
Ratings
Analyst Maintains Hold on Fate Therapeutics as Off‑the‑Shelf CAR‑T Pipeline Advances but Key Efficacy Data Remain Early
2M ago
FATE
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
PremiumThe Fly
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
2M ago
FATE
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
PremiumThe Fly
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
2M ago
FATE
Fate Therapeutics intiates first patient in RECLAIM-LN trial
PremiumThe Fly
Fate Therapeutics intiates first patient in RECLAIM-LN trial
2M ago
FATE
Fate Therapeutics price target raised to $8 from $6 at Piper Sandler
PremiumThe Fly
Fate Therapeutics price target raised to $8 from $6 at Piper Sandler
2M ago
FATE
FATE Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsFATE Upcoming Earnings Report: What to Expect?
3M ago
FATE
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
Premium
Ratings
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
3M ago
FATE
Fate Therapeutics announces FDA clearance of FT839 IND application
Premium
The Fly
Fate Therapeutics announces FDA clearance of FT839 IND application
3M ago
FATE
Fate Therapeutics Shareholders Back Directors and Governance Plans
PremiumCompany Announcements
Fate Therapeutics Shareholders Back Directors and Governance Plans
4M ago
8K
FATE
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
PremiumCompany Announcements
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
5M ago
8K
FATE
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
PremiumRatings
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability
5M ago
FATE
Fate Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Fate Therapeutics management to meet with Piper Sandler
5M ago
FATE
5 Healthcare Stocks Set to Join the Russell 3000
PremiumMarket News5 Healthcare Stocks Set to Join the Russell 3000
5M ago
QSI
AGEN
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
Premium
Weekend Updates
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
5M ago
AMT
CTMX
Fate Therapeutics price target raised to $2.20 from $2 at BofA
Premium
The Fly
Fate Therapeutics price target raised to $2.20 from $2 at BofA
5M ago
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >